Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2016 - 2025)

Amphastar Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 13 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $8.1 million for Q4 2025, up 11.22% from a year ago — trailing twelve months through Dec 2025 was $31.6 million (down 13.03% YoY), and the annual figure for FY2025 was $31.6 million, up 12.03%.
  • Depreciation & Amortization (CF) for Q4 2025 was $8.1 million at Amphastar Pharmaceuticals, up from $7.9 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AMPH hit a ceiling of $9.8 million in Q3 2024 and a floor of $2.5 million in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $5.3 million (2022), compared with a mean of $5.8 million.
  • Peak annual rise in Depreciation & Amortization (CF) hit 215.9% in 2024, while the deepest fall reached 24.84% in 2024.
  • Amphastar Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.6 million in 2021, then skyrocketed by 32.28% to $3.4 million in 2022, then skyrocketed by 180.86% to $9.7 million in 2023, then fell by 24.84% to $7.3 million in 2024, then increased by 11.22% to $8.1 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $8.1 million (Q4 2025), $7.9 million (Q3 2025), and $8.3 million (Q2 2025) per Business Quant data.